[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 16, 1994

β-Agonist Use and Death from Asthma

Author Affiliations

McGill University Faculty of Medicine Montreal, Quebec

JAMA. 1994;271(11):821-822. doi:10.1001/jama.1994.03510350029019
Abstract

To the Editor.  —Mullen et al1 apply a meta-analysis to five epidemiologic studies to conclude that the use of inhaled β-agonists by metered-dose inhaler is not associated with the risk of death from asthma. This conclusion is in direct contradiction to the conclusions of the four largest source studies used in their meta-analysis. We submit that this apparent inconsistency is the result of serious methodological flaws in the comparison of "did vs did not use β-agonist" employed in their meta-analysis.This comparison does not correspond to the contrasts designed or performed in the four principal source studies. The three New Zealand2-4 studies were clearly comparing fenoterol with albuterol,2 finding a higher risk for the former. Our study5 focused on the dose-response analysis, which showed, for example, that in patients using any β-agonist the risk of asthma death for those using more than two canisters per month

First Page Preview View Large
First page PDF preview
First page PDF preview
×